Style | Citing Format |
---|---|
MLA | Razazian N, et al.. "Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020)." Multiple Sclerosis and Related Disorders, vol. 57, no. , 2022, pp. -. |
APA | Razazian N, Eskandarieh S, Siabani S, Afshari D, Sahraian MA, Khezri O, Rezaei M, Fakhri N (2022). Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020). Multiple Sclerosis and Related Disorders, 57(), -. |
Chicago | Razazian N, Eskandarieh S, Siabani S, Afshari D, Sahraian MA, Khezri O, Rezaei M, Fakhri N. "Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020)." Multiple Sclerosis and Related Disorders 57, no. (2022): -. |
Harvard | Razazian N et al. (2022) 'Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020)', Multiple Sclerosis and Related Disorders, 57(), pp. -. |
Vancouver | Razazian N, Eskandarieh S, Siabani S, Afshari D, Sahraian MA, Khezri O, et al.. Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020). Multiple Sclerosis and Related Disorders. 2022;57():-. |
BibTex | @article{ author = {Razazian N and Eskandarieh S and Siabani S and Afshari D and Sahraian MA and Khezri O and Rezaei M and Fakhri N}, title = {Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020)}, journal = {Multiple Sclerosis and Related Disorders}, volume = {57}, number = {}, pages = {-}, year = {2022} } |
RIS | TY - JOUR AU - Razazian N AU - Eskandarieh S AU - Siabani S AU - Afshari D AU - Sahraian MA AU - Khezri O AU - Rezaei M AU - Fakhri N TI - Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020) JO - Multiple Sclerosis and Related Disorders VL - 57 IS - SP - EP - PY - 2022 ER - |